Pamuk G.E.Dönmez S.Turgut B.Yeşil N.Tekgündüz E.Demir M.Vural Ö.2024-06-122024-06-1220061300-0292https://hdl.handle.net/20.500.14551/17331Objective: To determine the general clinical features, treatment modalities and response to therapy, survival and the importance of prognostic factors that might influence survival in chronic lymphocytic leukemia (CLL) patients diagnosed at our center. Material and Methods: We evaluated 65 CLL patients (39 males, 26 females, median age: 64) followed up at Trakya University Medical Faculty, Department of Internal Medicine, Division of Hematology between 1998 and 2005. Rai staging system was used for clinical staging. Results: At initial diagnosis, 4 cases (6.2%) had stage 0, 14 (21.5%) stage I, 20 (30.8%) stage II, 10 (15.4%) stage III, and 17 (26.2%) stage IV disease. Five patients (7.9%) were asymptomatic at initial presentation. According to Rai stages, 4 were early-stage (Rai 0, I, II) and 3 were advanced-stage (Rai III, IV) patients. Autoimmune hemolytic anemia was detected in 7 (10.8%) and secondary malignancy in 6 (9.2%) CLL patients. When CLL was diagnosed, 23 early Rai stage patients (60.5%) and 22 (80.5%) late Rai stage patients were treated. Best response to first-line therapy (55.6%) was achieved with chlorambucil. The median survival of subjects with early-stage disease at initial diagnosis was 130 months, and that of advanced-stage subjects was 118 months (p= 0.04). Five- and 10-year survival rate was 77% and 49% respectively. Cox multivariable regression analysis showed that having advanced-stage disease at diagnosis (OR: 4.2, p= 0.01) and age >60 years (OR: 5.6, p= 0.036) were independently poor prognostic parameters. Conclusion: The results of this study suggest that advanced-stage disease and age >60 years at initial diagnosis are poor prognostic parameters in CLL patients. Copyright © 2006 by Türkiye Klinikleri.trinfo:eu-repo/semantics/closedAccessB-Cell; Chlorambucil; Chronic; Leukemia; LymphocytosisChlorambucil; Fludarabine; Adult; Article; Autoimmune Hemolytic Anemia; Cancer Patient; Cancer Staging; Cancer Survival; Cancer Therapy; Chronic Lymphatic Leukemia; Clinical Evaluation; Clinical Feature; Controlled Study; Female; Follow Up; Human; Major Clinical Study; Male; Metastasis; Prognosis; Proportional Hazards Model; University HospitalArticle2666116162-s2.0-33845986727Q4